This podcast will help participants to understand advances in I-O biomarker testing, advantages and limitations of some key I-O biomarkers, and practical ways that pathologists and laboratory professionals can improve their I-O biomarker testing workflows to optimize patient care.
Course topics include:
- Recent advances in immune-oncology (I-O) biomarker testing
- Advantages and limitations of IO biomarkers
- Addressing challenges related to IO biomarkers
- Improving IO biomarker workflows
- Best practices for collaboration with the multidisciplinary cancer care team
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
Learning Objectives
Upon completion of this activity, you will be able to:
- Discuss strategies and techniques for optimizing the examination of resection specimens following neoadjuvant immunotherapy
- Explore ways to strengthen collaboration and communication between pathologists and oncologists regarding resected samples following neoadjuvant immunotherapy
- Describe the current state and future directions of cancer immunotherapy biomarkers and their implications for pathology practice
- Compare and contrast the advantages and limitations of different types of I-O biomarkers (eg, PD-L1, TMB, MSI)
- Optimize laboratory protocols and workflows for I-O biomarker testing (eg, gross examination, tissue fixation, processing, storage, staining, scoring, reporting, interpretation, and use of liquid biopsy and next generation sequencing [NGS])
- Explore ways to strengthen collaboration and communication between pathologists and oncologists as new data on I-O biomarkers emerges
Faculty
Kurt Schalper, MD, PhD
Associate Professor of Pathology
Director, Translational Immuno-oncology Laboratory
Yale School of Medicine, New Haven, Connecticut
Janis Taube, M.D.
Professor, Department of Dermatology
Director, Division of Dermatopathology
Johns Hopkins University School of Medicine, Baltimore, MD
Faculty Disclosures
All relevant financial relationships for Kurt Schalper and Janis Taube have been mitigated.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of .75 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.
Method of Participation
To complete the activity and receive credit, the participant must participate in the course. CME certificates will be provided online.
Commercial Support
This activity is supported by an independent educational grant from Bristol Myers Squibb.